期刊文献+

万古霉素在肥胖人群与正常人群中药动学参数的系统评价 被引量:5

Pharmacokinetic parameters of vancomycin in obese and normal population:a systematic review
下载PDF
导出
摘要 目的:通过Meta分析比较万古霉素在肥胖人群和非肥胖正常人群中的药代动力学特点。方法:在Medline、Sciencedirect、Cochrane、CEPS、CETD、CNKI、万方数据库系统搜索相关文献。采用Rev Man4.2软件对其统计分析。结果:总计5篇研究被纳入分析。Meta结果表明:肥胖人群的万古霉素清除率(clearance,CL),稳态表观分布容积(volume of distribution at steady state,Vdss)比正常人群更高。清除率与理想体质量的比值(clearance/ideal body weight,CL/IBW)以及分布容积与理想体质量的比值(volume of distribution/ideal body weight,Vd/IBW)在肥胖人群中更高。但是,清除率与总体质量的比值(clearance/total body weight,CL/TBW)在2组中没有差异。结论:虽然肥胖人群的万古霉素CL和Vdss比正常人群更高,但是2组中的CL/TBW没有差异。 Objective:To compare the pharmacokinetic characteristics between obese and normal patients. Methods:The databases of Medline,Sciencedirect,Cochrane,CEPS,CETD,CNKI and Wan Fang were systematically searched. Rev Man4.2 was used for meta-analysis. Results:A total of 5 researches were included in the research. Meta analysis showed that vancomycin clearance(CL) and distribution volume at steady state(Vdss)were significantly higher in obese population than in normal population. Obese population had higher CL/IBW and Vd/IBW. However,there was no significant difference in CL/TBW between the two groups. Conclusion:CL and Vdss are significantly higher in obese population,but CL/TBW is similar in the two groups.
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2015年第2期309-313,共5页 Journal of Chongqing Medical University
关键词 肥胖 万古霉素 META分析 药动学 obesity vancomycin Meta analysis pharmacokinetics
  • 相关文献

参考文献13

  • 1Grace E.Altered vancomycin pharmacokinetics in obese and mor- bidly obese patients:what we have learned over the past 30 years[J].J Antimicrob Chemother, 2012,67 (6) : 1305-1310.
  • 2Martin JH,Norris R,Barras M,et al.Therapeutic monitoring of van- comycin in aduh patients:a consefisus review of the American society of health-system pharmacists, the infectious diseases society of America, and the Society of infectious diseases pharmacists[J].Clin Biochem Rev, 2010,31(1) :21-24.
  • 3Higgins JP,Thompson SG,Deeks JJ,et al.Measuring inconsistency in Meta-analyses[J].BMJ, 2003,327(7414) : 557-560.
  • 4Bauer LA,Black DJ,LiU JS.Vancomycin dosing in morbidly obese patients[J].Eur J Clin Pharmaeol, 1998,54(8) :621-625.
  • 5Blouin RA, Bauer LA, Miller DD, et al.Vancomyein pharmaeoki- neties in normal and morbidly obese subjects[J].Antimicrob Agents Che- mother, 1982,21 (4) :575-580.
  • 6Yeh CL,Wang HY, Chan A.Retrospective evaluation of vancomycin therapeutic drug monitoring in obese patients in a medical center[J].The Journal of TAIWAN Pharmacy ,2010,26(4) :82-92.
  • 7Ducharme MP,Slaughter RL,Edwards DJ.Vancomycin pharmacoki- netics in a patient population:effect of age, gender, and body weight[J]. Ther Drug Monit, 1994,16(5) :513-518.
  • 8Vance-Bryan K,Guay DR,Gilliland SS,et al.Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique[J].Antimicrob Agents Chemother, 1993, 37(3) :436-440.
  • 9Hanley MJ,Abernethy DR, Greenblatt DJ.Effect of Obesity on the pharmacokinetics of drugs in humans[J].Clin Pharmacokinet,2010,49 (2):71-87.
  • 10Chagnac A,Weinstein T,Korzets A,et al.Glomerular hemody- namics in severe obesity[J].Am J Physiol Renal Physiol,2000,278(5) : F817-F822.

同被引文献36

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部